Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Sarclisa (isatuximab-irfc) for the Treatment of Multiple Myeloma

Drug Name

Sarclisa (isatuximab-irfc)

Developer

Sanofi-Aventis

Product Description

Monoclonal antibody (mAb)

Therapy Class

Anti-CD38 mAb

Current Indication

Multiple myeloma

Market Sector

Oncology

Development Status

Approved in the US and Europe
Expand
Close
Close
Close

Go Top